UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 _____________________________________________ FORM 10-Q _____________________________________________ ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | |------------------------------------------------------------------|---------------------- ...

Corporate Presentation Cautionary statement regarding forward-looking information Certain statements made in this slide presentation may constitute forward-looking information within the meaning of applicable Canadian securities law and forward-looking statements within the meaning of applicable United States securities law. These forward-looking statements or information include but are not limited to statements or information with respect to: Aurinia’s estimates as to its unaudited net revenues and produc ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ET Company Participants Jamie Harrell - Director of Corporate Communications & Corporate Affairs Peter Greenleaf - President & Chief Executive Officer Joseph Miller - Chief Financial Officer Conference Call Participants Maurice Raycroft - Jefferies Olivia Brayer - Cantor Fitzgerald Stacy Ku - Cowen Ed Arce - H.C. Wainwright Joseph Schwartz - SVB Securities Justin Kim - Oppenheimer Operator Greetings, and we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________________________________________ Form 10-K ___________________________________________________________________________________ ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | --- | --- | --- | |---- ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q3 2022 Earnings Conference Call November 3, 2022 8:30 AM ET Company Participants Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief Financial Officer Conference Call Participants Ed Arce - H.C. Wainwright Joseph Schwartz - SVB Securities Ken Cacciatore - Cowen & Company Justin Kim - Oppenheimer & Company Sahil Dhingra - RBC Capital Markets David Martin - Bloom Burton Maury Raycroft - Jefferies Operator Greetings, and welcome to Aurinia Pharma ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants DeDe Sheel – Vice President-Investor Relations Peter Greenleaf – President and Chief Executive Officer Joe Miller – Chief Financial Officer Neil Solomons – Chief Medical Officer Conference Call Participants Ed Arce – HC Wainwright Justin Kim – Oppenheimer Olivia Brayer – Cantor Fitzgerald Sahil Dhingra – RBC Operator Greetings, and welcome to Aurinia Pharmaceuticals Second Quarter 2022 ...

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Dana Lynch - Director of Corporate Communications & Corporate Affairs Peter Greenleaf - President & Chief Executive Officer Joe Miller - Chief Financial Officer Max Colao - Chief Commercial Officer Neil Solomons - Chief Medical Officer Conference Call Participants Olivia Brayer - Cantor Fitzgerald Maury Raycroft - Jeffries Stacy Ku - Cowen and Company Ed Arce - HC Wainwright Sahil Dhingra ...